Annals of Hematology

Papers
(The H4-Index of Annals of Hematology is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Mechanism of thrombocytopenia in COVID-19 patients347
Blood type and outcomes in patients with COVID-19222
Hematological findings in coronavirus disease 2019: indications of progression of disease117
COVID-19 in cancer patients: clinical characteristics and outcome—an analysis of the LEOSS registry116
Signals of Th2 immune response from COVID-19 patients requiring intensive care98
COVID-19-driven endothelial damage: complement, HIF-1, and ABL2 are potential pathways of damage and targets for cure83
Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry59
Clozapine-induced agranulocytosis57
Management of myelofibrosis after ruxolitinib failure56
Thrombotic complications and anticoagulation in COVID-19 pneumonia: a New York City hospital experience55
Hematologic disorders associated with COVID-19: a review53
Central venous catheter–related infections in hematology and oncology: 2020 updated guidelines on diagnosis, management, and prevention by the Infectious Diseases Working Party (AGIHO) of the German S52
Association between ABO blood types and coronavirus disease 2019 (COVID-19), genetic associations, and underlying molecular mechanisms: a literature review of 23 studies51
Characteristics of coagulation alteration in patients with COVID-1949
Coagulopathy and thromboembolic events in patients with SARS-CoV-2 infection: pathogenesis and management strategies49
Autoimmune thrombotic thrombocytopenic purpura (TTP) associated with COVID-1947
COVID-19 infection associated with autoimmune hemolytic anemia44
Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes43
Impact of rituximab on COVID-19 outcomes43
Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working 38
Hematologic changes predict clinical outcome in recovered patients with COVID-1936
Prognostic significance of hemoglobin level and autoimmune hemolytic anemia in SARS-CoV-2 infection35
Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents—a retrospective multicenter analysis on behalf of the Ge33
Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes32
Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma32
Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infect32
Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma29
Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy29
Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in elderly HL: a two-center experience in 123 patients29
Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies29
0.026648998260498